Debt-to-equity of Vivos Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Vivos Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
Vivos Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 302%, a 17% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Vivos Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	302%	+44%	+17%	30 Sep 2025
Q2 2025	176%	-383%	-69%	30 Jun 2025
Q1 2025	119%	-1263%	-91%	31 Mar 2025
Q4 2024	158%	-285%	-64%	31 Dec 2024
Q3 2024	258%	-36%	-12%	30 Sep 2024
Q2 2024	559%	+394%	+239%	30 Jun 2024
Q1 2024	1382%	+1280%	+1259%	31 Mar 2024
Q4 2023	443%	+373%	+530%	31 Dec 2023
Q3 2023	294%	+245%	+502%	30 Sep 2023
Q2 2023	165%	+128%	+346%	30 Jun 2023
Q1 2023	102%	+71%	+237%	31 Mar 2023
Q4 2022	70%	+39%	+125%	31 Dec 2022
Q3 2022	49%	+15%	+43%	30 Sep 2022
Q2 2022	37%			30 Jun 2022
Q1 2022	30%			31 Mar 2022
Q4 2021	31%			31 Dec 2021
Q3 2021	34%			30 Sep 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.